{"id":"https://openalex.org/W7149008366","doi":"https://doi.org/10.1158/1538-7445.am2026-395","title":"Abstract 395: Identification of drug resistance factors in ALK-rearranged lung cancer using genome-wide CRISPR activation screening.","display_name":"Abstract 395: Identification of drug resistance factors in ALK-rearranged lung cancer using genome-wide CRISPR activation screening.","publication_year":2026,"publication_date":"2026-04-03","ids":{"openalex":"https://openalex.org/W7149008366","doi":"https://doi.org/10.1158/1538-7445.am2026-395"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2026-395","doi":"https://doi.org/10.1158/1538-7445.am2026-395","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-395","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043358223","display_name":"Mai Nagasaka","orcid":"https://orcid.org/0009-0005-7782-6630","observed_orcids":["https://orcid.org/0009-0005-7782-6630"]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Mai Nagasaka","raw_affiliation_strings":["Japanese Foundation for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Foundation for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049775713","display_name":"Marie Kawahara","orcid":"https://orcid.org/0009-0005-8684-2691","observed_orcids":["https://orcid.org/0009-0005-8684-2691"]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Marie Kawahara","raw_affiliation_strings":["Japanese Foundation for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Foundation for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083962517","display_name":"Ken Uchibori","orcid":"https://orcid.org/0000-0003-1491-923X","observed_orcids":["https://orcid.org/0000-0003-1491-923X"]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ken Uchibori","raw_affiliation_strings":["Japanese Foundation for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Foundation for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078287634","display_name":"Makoto Nishio","orcid":"https://orcid.org/0000-0003-4969-4165","observed_orcids":["https://orcid.org/0000-0003-4969-4165"]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Makoto Nishio","raw_affiliation_strings":["Japanese Foundation for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Foundation for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5011207225","display_name":"Ryohei Katayama","orcid":"https://orcid.org/0000-0001-7394-895X","observed_orcids":["https://orcid.org/0000-0001-7394-895X"]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ryohei Katayama","raw_affiliation_strings":["Japanese Foundation for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Foundation for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I42570316"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"86","issue":"7_Supplement","first_page":"395","last_page":"395"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10878","display_name":"CRISPR and Genetic Engineering","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alk-rearrangement","display_name":"ALK rearrangement","score":0.8889999985694885},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9679999947547913},{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.968999981880188},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8600000143051147},{"id":"https://openalex.org/keywords/crispr-activation-screen","display_name":"CRISPR activation screen","score":0.9369999766349792},{"id":"https://openalex.org/keywords/gain-of-function-screen","display_name":"gain-of-function screen","score":0.7279999852180481},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.6700000166893005},{"id":"https://openalex.org/keywords/met","display_name":"MET","score":0.9980000257492065},{"id":"https://openalex.org/keywords/fgfr1","display_name":"FGFR1","score":0.9909999966621399},{"id":"https://openalex.org/keywords/bcl-2","display_name":"Bcl-2","score":0.9900000095367432},{"id":"https://openalex.org/keywords/alectinib","display_name":"alectinib","score":0.7070000171661377},{"id":"https://openalex.org/keywords/lorlatinib","display_name":"lorlatinib","score":0.9729999899864197},{"id":"https://openalex.org/keywords/brigatinib","display_name":"brigatinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bypass-signaling","display_name":"bypass signaling","score":0.5049999952316284},{"id":"https://openalex.org/keywords/receptor-tyrosine-kinases","display_name":"receptor tyrosine kinase","score":0.7179999947547913},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.3630000054836273},{"id":"https://openalex.org/keywords/in-vivo-drug-resistance","display_name":"in vivo drug resistance","score":0.3400000035762787},{"id":"https://openalex.org/keywords/patient-derived-cell-lines","display_name":"patient-derived cell lines","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6589999794960022},{"id":"https://openalex.org/C98108389","wikidata":"https://www.wikidata.org/wiki/Q412563","display_name":"CRISPR","level":3,"score":0.6424000263214111},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5882999897003174},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5286999940872192},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.4343999922275543},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.42640000581741333},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4253000020980835},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.41679999232292175},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4043000042438507},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40400001406669617},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3935999870300293},{"id":"https://openalex.org/C101544691","wikidata":"https://www.wikidata.org/wiki/Q420511","display_name":"Receptor tyrosine kinase","level":3,"score":0.38999998569488525},{"id":"https://openalex.org/C88045685","wikidata":"https://www.wikidata.org/wiki/Q174576","display_name":"Activator (genetics)","level":3,"score":0.33980000019073486},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3336000144481659},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.32600000500679016},{"id":"https://openalex.org/C132455925","wikidata":"https://www.wikidata.org/wiki/Q16965677","display_name":"Cas9","level":4,"score":0.31619998812675476},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.3127000033855438},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.2955999970436096},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.2851000130176544},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.2838999927043915},{"id":"https://openalex.org/C32619005","wikidata":"https://www.wikidata.org/wiki/Q24768234","display_name":"Protein kinase domain","level":4,"score":0.28119999170303345},{"id":"https://openalex.org/C172512520","wikidata":"https://www.wikidata.org/wiki/Q5768379","display_name":"Hippo signaling pathway","level":3,"score":0.26910001039505005},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2574000060558319},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.2502000033855438}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2026-395","doi":"https://doi.org/10.1158/1538-7445.am2026-395","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-395","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4409630478","https://openalex.org/W4393076154","https://openalex.org/W2113327188","https://openalex.org/W2986537855","https://openalex.org/W3195755339","https://openalex.org/W2765129546","https://openalex.org/W1992224406","https://openalex.org/W2556150586","https://openalex.org/W2586889471","https://openalex.org/W2782740441"],"abstract_inverted_index":{"Abstract":[0],"Anaplastic":[1],"lymphoma":[2],"kinase":[3,18,75],"(ALK)-rearrangements":[4],"occur":[5],"in":[6,72,89,126,202,223,236,297,304,315,367],"approximately":[7],"2-5%":[8],"of":[9,63,79,93,110,146,166,173,263,273,319,329,363,379],"non-small":[10],"cell":[11,130,267],"lung":[12,369],"cancers":[13],"(NSCLC).":[14],"Several":[15],"ALK":[16,74],"tyrosine":[17,240],"inhibitors":[19],"(ALK-TKIs)":[20],"have":[21,35,66],"been":[22,67],"developed,":[23],"and":[24,55,77,177,220,247,271,289,324],"six":[25],"are":[26],"currently":[27],"approved":[28],"for":[29,103,217,341,383],"clinical":[30,38,53],"use.":[31],"Although":[32],"these":[33,334],"therapies":[34],"markedly":[36],"improved":[37],"outcomes,":[39],"most":[40],"patients":[41],"eventually":[42],"relapse":[43],"due":[44],"to":[45,106,132,138,155,171,180,266],"acquired":[46],"drug":[47,364],"resistance,":[48,343],"which":[49,293],"remains":[50],"a":[51,90,119,151,193],"significant":[52,91,261],"challenge":[54],"limits":[56],"long-term":[57],"survival.":[58],"To":[59],"date,":[60],"numerous":[61],"mechanisms":[62,97],"ALK-TKI":[64,111,342],"resistance":[65,137,179,365],"identified,":[68],"including":[69,322],"secondary":[70],"mutations":[71],"the":[73,95,101,156,174,183,210,224,252,277,283,303,327,330,380],"domain":[76],"activation":[78,122,145,374],"bypass":[80],"signaling":[81,275],"pathways,":[82],"such":[83,243],"as":[84,244,249,251],"EGFR":[85,323],"or":[86,168,215],"MET.":[87],"However,":[88],"number":[92],"cases,":[94],"underlying":[96],"remain":[98],"unknown,":[99],"highlighting":[100],"need":[102],"unbiased":[104],"approaches":[105],"identify":[107,133],"novel":[108,338],"drivers":[109],"resistance.":[112],"In":[113,160],"this":[114],"study,":[115],"we":[116],"first":[117],"performed":[118,207],"genome-wide":[120,184,372],"CRISPR":[121,373],"(CRISPRa)":[123],"gain-of-function":[124],"screen":[125,205,307],"patient-derived":[127],"ALK-positive":[128],"NSCLC":[129],"lines":[131],"genetic":[134],"pathways":[135,264],"conferring":[136],"ALK-TKIs.":[139,181],"The":[140,201,233,280],"CRISPRa":[141,185,204,306],"system":[142],"enables":[143],"sgRNA-directed":[144],"endogenous":[147],"genes":[148],"via":[149],"dCas9-VP64,":[150,164],"nuclease-dead":[152],"Cas9":[153],"fused":[154],"transcriptional":[157],"activator":[158],"VP64.":[159],"JFCR-028-3":[161,237],"cells":[162,187,211,227],"expressing":[163,188],"introduction":[165],"sgEGFR":[167],"sgMET":[169],"led":[170],"upregulation":[172],"targeted":[175],"proteins":[176],"conferred":[178],"For":[182],"screen,":[186],"dCas9-VP64":[189],"were":[190,228],"transduced":[191],"with":[192,212,282,317],"pooled":[194],"sgRNA":[195],"library":[196],"targeting":[197],"over":[198],"18,000":[199],"genes.":[200,279],"vitro":[203],"was":[206],"by":[208,230],"culturing":[209],"alectinib,":[213],"lorlatinib,":[214],"brigatinib":[216],"nine":[218],"days,":[219],"sgRNAs":[221],"enriched":[222],"surviving":[225],"drug-tolerant":[226],"analyzed":[229],"next-generation":[231],"sequencing.":[232],"top-ranked":[234],"hits":[235,310],"included":[238],"receptor":[239],"kinases":[241],"(RTKs)":[242],"EGFR,":[245],"MET,":[246],"FGFR1,":[248],"well":[250],"anti-apoptotic":[253],"factor":[254],"BCL2.":[255],"Gene":[256],"ontology":[257],"analysis":[258],"further":[259],"revealed":[260,308],"enrichment":[262,318],"related":[265],"proliferation,":[268],"RTK":[269],"signaling,":[270],"regulation":[272],"apoptotic":[274],"among":[276],"hit":[278,291],"screens":[281],"three":[284],"ALK-TKIs":[285],"identified":[286],"both":[287],"shared":[288],"drug-specific":[290],"genes,":[292],"may":[294],"reflect":[295],"differences":[296],"their":[298],"off-target":[299],"inhibitory":[300],"profiles.":[301],"Furthermore,":[302],"vivo":[305],"top":[309],"that":[311],"differed":[312],"from":[313],"those":[314],"vitro,":[316],"ligand-dependent":[320],"factors,":[321],"KIT,":[325],"reflecting":[326],"influence":[328],"physiological":[331],"microenvironment.":[332],"Together,":[333],"results":[335],"reveal":[336],"multiple":[337],"factors":[339,366],"responsible":[340],"providing":[344],"insight":[345],"into":[346],"previously":[347],"unidentified":[348],"mechanisms.":[349],"Citation":[350],"Format:":[351],"Mai":[352],"Nagasaka,":[353],"Marie":[354],"Kawahara,":[355],"Ken":[356],"Uchibori,":[357],"Makoto":[358],"Nishio,":[359],"Ryohei":[360],"Katayama.":[361],"Identification":[362],"ALK-rearranged":[368],"cancer":[370],"using":[371],"screening":[375],"[abstract].":[376],"In:":[377],"Proceedings":[378],"American":[381],"Association":[382],"Cancer":[384,402],"Research":[385],"Annual":[386],"Meeting":[387],"2026;":[388],"Part":[389],"1":[390],"(Regular":[391],"Abstracts);":[392],"2026":[393],"Apr":[394],"17-22;":[395],"San":[396],"Diego,":[397],"CA.":[398],"Philadelphia":[399],"(PA):":[400],"AACR;":[401],"Res":[403],"2026;86(7":[404],"Suppl):Abstract":[405],"nr":[406],"395.":[407]},"counts_by_year":[],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2026-04-04T00:00:00"}